Radiation therapy for bladder cancer that has not responded to BCG
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether radiation therapy (high-energy beams to kill cancer cells) can be a good treatment for bladder cancer that hasn't gone away after BCG therapy, offering an alternative to surgery to remove the bladder. It aims to see if this approach can control the cancer while possibly preserving your bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a type of bladder cancer called high-risk non-muscle-invasive bladder cancer (cancer that has not grown deep into the bladder wall) that has not responded to BCG therapy.
- Your cancer is mostly urothelial (the type that lines the bladder), and you have carcinoma in situ (flat, high-grade cells) with or without other high-grade growths.
- You are not able to have surgery to remove the bladder, or you have chosen not to have that surgery.
- Your overall health is reasonably good (able to take care of yourself and up and about more than half of the day).
- You have not had radiation therapy to the pelvic area in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation therapy that adjusts to your body's changes during treatment. It aims to reduce side effects and improve accuracy for people with bladder cancer.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial tests whether adding radiation therapy to immunotherapy after bladder removal surgery can help prevent cancer from coming back. It's for people with advanced bladder cancer who have already started immunotherapy.
This study tests a newer way to remove bladder tumors (called ERBT) combined with BCG, a standard immunotherapy placed in the bladder, for people with bladder cancer that is not too advanced. The goal is to see if this combination helps reduce the chance of the cancer coming back.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.